NO20053776L - Diagnostic imaging agents with MMP inhibitory activity - Google Patents
Diagnostic imaging agents with MMP inhibitory activityInfo
- Publication number
- NO20053776L NO20053776L NO20053776A NO20053776A NO20053776L NO 20053776 L NO20053776 L NO 20053776L NO 20053776 A NO20053776 A NO 20053776A NO 20053776 A NO20053776 A NO 20053776A NO 20053776 L NO20053776 L NO 20053776L
- Authority
- NO
- Norway
- Prior art keywords
- diagnostic imaging
- inhibitory activity
- imaging agents
- pharmaceutical composition
- matrix metalloproteinases
- Prior art date
Links
- 238000002059 diagnostic imaging Methods 0.000 title abstract 6
- 239000012216 imaging agent Substances 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 3
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 239000002872 contrast media Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0302891A GB0302891D0 (en) | 2003-02-10 | 2003-02-10 | Diagnostic imaging agents for cardiovascular disease |
| GB0307524A GB0307524D0 (en) | 2003-04-01 | 2003-04-01 | Diagnostic imaging agents with MMP inhibitory activity |
| PCT/GB2004/000524 WO2004069365A1 (en) | 2003-02-10 | 2004-02-10 | Diagnostic imaging agents with mmp inhibitory activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20053776D0 NO20053776D0 (no) | 2005-08-09 |
| NO20053776L true NO20053776L (no) | 2005-09-30 |
Family
ID=32852413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20053776A NO20053776L (no) | 2003-02-10 | 2005-08-09 | Diagnostic imaging agents with MMP inhibitory activity |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8231858B2 (enExample) |
| EP (1) | EP1592458A1 (enExample) |
| JP (1) | JP2006519216A (enExample) |
| AU (1) | AU2004210208B2 (enExample) |
| CA (1) | CA2514885A1 (enExample) |
| NO (1) | NO20053776L (enExample) |
| RU (1) | RU2005123801A (enExample) |
| WO (1) | WO2004069365A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0326546D0 (en) * | 2003-11-14 | 2003-12-17 | Amersham Plc | Inhibitor imaging agents |
| GB0421308D0 (en) * | 2004-09-24 | 2004-10-27 | Amersham Plc | Enzyme inhibitor imaging agents |
| US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
| JP5368099B2 (ja) | 2005-10-07 | 2013-12-18 | ゲルベ | ガリウムと錯体形成することが可能なシグナル部分にカップリングされた、生物学的標的の認識のための部分を含んでなる化合物 |
| CA2913373C (en) | 2006-10-06 | 2017-11-07 | Mallinckrodt Llc | Self-aligning radioisotope elution system |
| EP2149568A1 (en) | 2008-07-22 | 2010-02-03 | Bracco Imaging S.p.A | Aryl-sulphonamidic dimers as metalloproteases inhibitors |
| EP2147684A1 (en) * | 2008-07-22 | 2010-01-27 | Bracco Imaging S.p.A | Diagnostic Agents Selective Against Metalloproteases |
| US9153350B2 (en) | 2011-01-19 | 2015-10-06 | Mallinckrodt Llc | Protective shroud for nuclear pharmacy generators |
| US8866104B2 (en) | 2011-01-19 | 2014-10-21 | Mallinckrodt Llc | Radioisotope elution system |
| US8809804B2 (en) * | 2011-01-19 | 2014-08-19 | Mallinckrodt Llc | Holder and tool for radioisotope elution system |
| WO2013010573A1 (en) * | 2011-07-18 | 2013-01-24 | Universitaet Muenster | Compounds with matrix-metalloproteinase inhibitory activity |
| US9023318B2 (en) * | 2011-06-08 | 2015-05-05 | Siemens Medical Solutions Usa, Inc. | Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof |
| EP2775906B1 (en) | 2011-11-11 | 2019-07-03 | Yale University | Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging |
| EP2644601A1 (en) * | 2012-03-28 | 2013-10-02 | Westfälische Wilhelms-Universität Münster | Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof |
| GB202012671D0 (en) * | 2020-08-13 | 2020-09-30 | Nrf Ithemba Labs | Theranostic Compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4427646A (en) * | 1981-04-02 | 1984-01-24 | Research Corporation | Use of radiolabeled peptide derived from crosslinked fibrin to locate thrombi in vivo |
| US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
| TW453995B (en) * | 1995-12-15 | 2001-09-11 | Novartis Ag | Certain alpha-substituted arylsulfonamido acetohydroxamic acids |
| AU7294098A (en) * | 1997-05-09 | 1998-11-27 | Agouron Pharmaceuticals, Inc. | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses |
| US6656448B1 (en) * | 2000-02-15 | 2003-12-02 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
| US6989139B2 (en) * | 2000-02-15 | 2006-01-24 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
| AU2001265182A1 (en) * | 2000-05-30 | 2001-12-11 | Rafael Fridman | Inhibitors of matrix metalloproteinases |
-
2004
- 2004-02-10 US US10/544,945 patent/US8231858B2/en not_active Expired - Fee Related
- 2004-02-10 RU RU2005123801/15A patent/RU2005123801A/ru not_active Application Discontinuation
- 2004-02-10 WO PCT/GB2004/000524 patent/WO2004069365A1/en not_active Ceased
- 2004-02-10 CA CA002514885A patent/CA2514885A1/en not_active Abandoned
- 2004-02-10 EP EP04709657A patent/EP1592458A1/en not_active Withdrawn
- 2004-02-10 JP JP2006502261A patent/JP2006519216A/ja active Pending
- 2004-02-10 AU AU2004210208A patent/AU2004210208B2/en not_active Ceased
-
2005
- 2005-08-09 NO NO20053776A patent/NO20053776L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004069365A1 (en) | 2004-08-19 |
| CA2514885A1 (en) | 2004-08-19 |
| EP1592458A1 (en) | 2005-11-09 |
| JP2006519216A (ja) | 2006-08-24 |
| WO2004069365A8 (en) | 2004-09-30 |
| RU2005123801A (ru) | 2006-03-27 |
| AU2004210208B2 (en) | 2007-06-07 |
| NO20053776D0 (no) | 2005-08-09 |
| AU2004210208A1 (en) | 2004-08-19 |
| US8231858B2 (en) | 2012-07-31 |
| US20070071670A1 (en) | 2007-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20053776L (no) | Diagnostic imaging agents with MMP inhibitory activity | |
| WO2004074434A3 (en) | Methods and compositions for administering therapeutic and diagnostic agents | |
| BR0214343A (pt) | Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1 | |
| EP1562897A4 (en) | PHENYL ACARBOXAMIDE AS A BETA SEKRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER | |
| BRPI0513959A (pt) | anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos | |
| BRPI0517803A (pt) | pirazolpirimidinas 1,4-substituìdas como inibidores de cinase | |
| WO2006044497A3 (en) | Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease | |
| NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
| BRPI0713755A8 (pt) | composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo | |
| DK2157192T3 (da) | Sammensætninger til diagnose og terapi af sygdomme forbundet med afvigende ekspression af futriner (R-spondiner) | |
| NO20075365L (no) | 3,4-substituerte pyrrolidinderivater for behandling av hypertensjon | |
| EA200602196A1 (ru) | Производные пиразола, композиции, содержащие эти соединения, и способы применения | |
| BRPI0714885B8 (pt) | compostos terapêuticos e seu uso | |
| NO20076053L (no) | Pyrazolpyrimidinderivat for behandling og forebygging av leversykdom | |
| BRPI0519443A2 (pt) | composto orgÂnicos | |
| DE602004030017D1 (de) | Heterocyclische verbindungen als nützliche malonyl-coa decarboxylase-hemmer | |
| TW200738698A (en) | Organic compounds | |
| MX2007011009A (es) | Compuestos de piperidina 3,4,5-substituidos. | |
| ATE384519T1 (de) | Hemmer-darstellende mittel | |
| WO2007006534A3 (en) | Piperidine derivatives useful in the diagnostic and therapeutic treatment of diseases depending on renin activity | |
| WO2006074924A8 (en) | 3,4,(5)-substituted tetrahvdropyridines | |
| TNSN08287A1 (en) | 3,5-substituted piperidine compounds as renin inhibitors | |
| WO2007144129A3 (en) | Pyrrolidine derivatives useful against diseases that depends on activity of renin | |
| TN2009000530A1 (en) | N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors | |
| BRPI0407350A (pt) | Combinações farmacêuticas compreendendo corticóides e imunosupressores para tratamento de doenças resistentes aos corticóides e/ou inibidores de calcineurina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |